A Rare Cause of Knee Pain Due to WarfarinToxicity: Spontaneous Suprapatellar Hematoma

Yıl 2013, Cilt: 3 Sayı: 3, 135 - 137, 01.09.2013

Attila Önmez Selçuk Yaylacı Ahmet Nalbant Abidin Karaaslan Tezcan Kaya Yasemin Gündüz Ali Tamer

https://doi.org/10.5505/sakaryamj.2013.28247

Öz

Warfarin is a widely used agent for the prevention of thromboembolic events. It should be used with caution, especially because of the risk of bleeding. Warfarin can cause hematuria, gastrointestinal bleeding, intracerebral bleeding, soft tissue hematomas, epistaxis, and retroperitoneal bleeding. In this article, we presented a 60-year-old female patient who was admitted to the emergency clinic with a spontaneous suprapatellar hematoma as a rare complication of warfarin overdose.

Anahtar Kelimeler

warfarin toxicity, knee pain, suprapatellar hematoma

Warfarin Toksisitesine Bağlı Nadir Bir Diz Ağrısı Nedeni: Spontan Suprapatellar Hematom

Öz

Warfarin, tromboembolik olayları engellemede yaygın olarak kullanılan bir ilaçtır. Özellikle kanama riski nedeni ile dikkatli kullanılması gerekmektedir. Warfarinin; hematüri, gastrointestinal kanamalar, intraserebral kanamalar, yumuşak doku hematomları, epistaksis ve retroperitoneal kanama gibi komplikasyonları bulunmaktadır. Bu yazıda diz ağrısı ile acil polikliniğine başvuran 60 yaşında kadın hastada travma öyküsü bulunmaksızın warfarin kullanımına bağlı nadir bir komplikasyon olan suprapatellar hematomu ele aldık.

Anahtar Kelimeler

warfarin toksisitesi, diz ağrısı, suprapatellar hematom

Kaynakça

• Landefeld S, Beyth R. Anticoagulantrelatedbleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315- 28
• Shah P, Kraklow W, Lamb G: Unusual complicationof warfarin coumadin sodium toxicity. Wis Med J 1994;93:212–214
• Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007;167:1414.
• Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment. Chest 2004;126:287-310.
• Fihn SD, Mc donell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin optimized outpatient Follow-up Study Group. Ann Intern med 1993;118:511-20
• Sudo A, Sano T, Horikawa K, Yamakawa T, Shi D, Uchida A. The incidence of deep vein thrombosis after hip and knee arthroplasties in Japanese patients: a prospective study. J OrthopSurg 2003; 11: 174–7.
• Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S
• Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensiıtivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009;84:1079-94.
• Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large terıtiary hospital. Critical Care 2008;12:R105.